Shares of West Pharmaceutical Services, Inc. (NYSE:WST) have earned an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.

Brokerages have set a 12-month consensus target price of $102.75 for the company and are predicting that the company will post $0.53 EPS for the current quarter, according to Zacks. Zacks has also assigned West Pharmaceutical Services an industry rank of 181 out of 265 based on the ratings given to related companies.

A number of research analysts have commented on WST shares. BidaskClub downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research note on Saturday, June 17th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $90.00 price objective on shares of West Pharmaceutical Services in a research note on Thursday, June 8th.

Institutional investors have recently bought and sold shares of the company. Acrospire Investment Management LLC bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth about $113,000. Citigroup Inc. lifted its position in shares of West Pharmaceutical Services by 95.1% in the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 765 shares during the last quarter. Harfst & Associates Inc. bought a new position in shares of West Pharmaceutical Services in the 1st quarter worth about $186,000. Wolverine Trading LLC bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth about $200,000. Finally, Tyers Asset Management LLC lifted its position in shares of West Pharmaceutical Services by 17.6% in the 1st quarter. Tyers Asset Management LLC now owns 2,464 shares of the medical instruments supplier’s stock worth $201,000 after buying an additional 368 shares during the last quarter. Institutional investors own 91.25% of the company’s stock.

West Pharmaceutical Services (NYSE:WST) traded up 2.42% during midday trading on Friday, hitting $91.43. 690,209 shares of the stock traded hands. The company’s 50-day moving average is $87.56 and its 200-day moving average is $88.98. West Pharmaceutical Services has a one year low of $70.17 and a one year high of $99.91. The company has a market cap of $6.77 billion, a PE ratio of 39.24 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.01. The business had revenue of $397.60 million during the quarter, compared to the consensus estimate of $406 million. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.59 earnings per share. Equities research analysts expect that West Pharmaceutical Services will post $2.68 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be given a $0.14 dividend. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend is Tuesday, October 17th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 22.22%.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/09/west-pharmaceutical-services-inc-wst-given-consensus-rating-of-buy-by-brokerages.html.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.